Spain Tumor Marker Testing Analyzers and Reagents Market, 2019-2023: Supplier Shares and Sales Segment Forecasts by Product--Competitive Intelligence, Technology and Instrumentation Review, Opportunities for Suppliers

Highlights

  • Comprehensive 565-page analysis of the Spanish tumor marker testing market.
  • Major issues pertaining to the Spanish laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.
  • Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.
  • Five-year test volume and sales forecasts over for 40 tumor marker performed in Spanish hospitals, commercial laboratories and physician offices.
  • Placements and installed base of automated and semi-automated analyzers used for tumor marker testing.
  • Current instrumentation technologies and feature comparison of leading analyzers.
  • Sales and market shares of leading suppliers.
  • Emerging diagnostic technologies and their potential market applications.
  • Product development opportunities.
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
  • Business opportunities and strategic recommendations for suppliers.

    and 85 tables



I. Introduction
II. Worldwide Market Overview
1. Market Overview
2. Worldwide Market Structure
3. Worldwide Market Size and Growth
III. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
VI. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
(continues)

VII. Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
(continues)
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha
(continues)

29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
(continues)
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opioid Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92
(continues)
- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
E. Personal Testing
(continues)
VIII. Spain Cancer Diagnostics Market
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Test Volume and Sales Forecasts by Market Segment,
Major Supplier Sales and Market Shares by Test
IX. Competitive Profiles
- Abbott
- AdnaGen/Alere
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Correlogic Systems/Vermillion
- Decode Genetics
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Elitech Group
- Enterix
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic/Gen-Probe
- Kreatech/Leica
- Kyowa Medex
- Mackay Life Sciences
- Myriad Genetics
- OncoLab
(continues)
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Quest Diagnostics
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Tosoh
- Thermo
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zila

X. Appendix: Major Universities and Research
Centers Developing Cancer Diagnostic
Technologies and Applications

List Of Tables



Tumor Marker Classification
Major Companies Developing or Marketing
ACTH Tests
Major Companies Developing or Marketing
AFP Tests
Major Companies Developing or Marketing
Beta-2 Microglobulin Tests
Major Companies Developing or Marketing
CA 15-3/27.29 Tests
Major Companies Developing or Marketing
CA 19-9 Tests
Major Companies Developing or Marketing
CA 125 Tests
Major Companies Developing or Marketing
Calcitonin Tests
Major Companies Developing or Marketing
CEA Tests
Major Companies Developing or Marketing
Estrogen Receptor Tests
Major Companies Developing or Marketing
Progesterone Receptor Tests
Major Companies Developing or Marketing
Ferritin Tests
Major Companies Developing or Marketing
Gastrin Tests
(continues)
Major Companies Developing or Marketing
HCG Tests

Major Companies Developing or Marketing
Insulin Tests

Major Companies Developing or Marketing
NSE Tests
Major Companies Developing or Marketing
Occult Blood Tests
Major Companies Developing or Marketing
PAP Smear/HPV Tests
Major Companies Developing or Marketing
PAP Tests
Major Companies Developing or Marketing
PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or Marketing
Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
(continues)
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis

Executive Summary Table: Spain, Total
Tumor Marker Test Volume and Sales
Forecast by Market Segment
Spain, Estimated Cancer Death Rates
Per 100,000 Population
Spain, Laboratories Performing Tumor
Marker Tests by Market Segment
Spain, Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
Spain, Commercial/Private Laboratories
Performing Tumor Markers by
Annual Test Volume
Spain, Total Tumor Marker Test Volume
Forecast by Market Segment
Spain, All Market Segment Major Cancer
Diagnostic Test Volume Forecast
Spain, Hospital Laboratories Major Cancer
Diagnostic Test Volume Forecast by Test
Spain, Commercial/Private Laboratories
Major Tumor Marker Test Volume Forecast
Spain, Total Tumor Marker Sales
Forecast by Market Segment
(continues)
Spain, All Market Segments Major Tumor
Marker Sales Forecast by Test
Spain, Hospital Laboratories Major Tumor
Marker Sales Forecast by Test
Spain, Commercial/Private Laboratories Major
Tumor Marker Sales Forecast by Test
Spain, AFP Test Volume and Diagnostics Sales
Forecast by Market Segment
Spain, Beta-2 Microglobulin Test Volume and
Diagnostics Sales Forecast by Market Segment
Spain, CA 15-3 Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, CA 19-9 Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, CA-125 Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, Calcitonin Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, CEA Test Volume and Diagnostics Sales
Forecast by Market Segment
Spain, Colon-Specific Antigen Test Volume and
Diagnostics Sales Forecast by Market Segment
Spain, Estrogen Receptor Test Volume and
Diagnostics Sales Forecast by Market Segment
Spain, Ferritin Test Volume and Diagnostics
Sales Forecast by Market Segment
(continues)
Spain, Gastrin Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, HCG Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, Insulin Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, Lymphocyte Subtyping
Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, NSE Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, Occult Blood Test Volume and
Diagnostics Sales Forecast by Market
Segment
Spain, Oncogenes Test Volume and
Diagnostics Sales Forecast by Market
Segment

Spain, Pancreatic Oncofetal Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, PAP Smear Test Volume and
Diagnostics Sales Forecast by Market
Segment
Spain, Parathyroid Hormone Test Volume
And Diagnostics Sales Forecast by Market
Segment
Spain, Progesterone Receptor
Test Volume and Diagnostics Sales Forecast
by Market Segment
(continues)
Spain, PAP Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, PSA Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, S-100 Protein Test Volume
And Diagnostics Sales Forecast by Market
Segment
Spain, Serotonin Test Volume and
Diagnostics Sales Forecast by Market
Segment
Spain, Sialic Acid Test Volume and
Diagnostics Sales Forecast by Market
Segment
Spain, Squamous Cell Carcinoma Antigen
Test Volume and Diagnostics Sales Forecast
by Market Segment
Spain, TDT Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, Thymidine Kinase
Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, Thyroglobulin
Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, TPA Test Volume and Diagnostics
Sales Forecast by Market Segment
Spain, Total Tumor Marker Sales by Major Suppliers
(continues)
Spain, AFP Testing Market Diagnostics
Sales by Major Supplier
Spain, CA 15-3/27.29 Testing Market
Diagnostics Sales by Major Supplier
Spain, 19-9 Testing Market Diagnostics
Sales by Major Supplier
Spain, CA 125 Testing Market Diagnostics
Sales by Major Supplier
Spain, CEA Testing Market Diagnostics
Sales by Major Supplier
Spain, PSA Testing Market Diagnostics
Sales by Major Supplier

Spain Hematology and Flow Cytometry Analyzers and Reagents Market for Over 40 Tests: Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review, Emerging Opportunities

LeadingMarketResearch.coms new study is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the Spanish hematology and flow cytometry markets during the next

USD 4500 View Report

Europe Hematology and Flow Cytometry Analyzers and Reagents Market for Over 40 Tests:France, Germany, Italy, Spain, UK--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

This comprehensive five-country report contains 450 pages, 160 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the European hematology

USD 17500 View Report

North America Tumor Marker Testing Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The North America Tumor Marker Testing market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million USD

USD 3000 View Report

Europe Tumor Marker Diagnostics Market, 2019-2023: France, Germany, Italy, Spain, UK--Market Share Analysis, Country Segment Forecasts, Competitive Intelligence, Instrumentation Review, Technology Trends, Opportunities for Suppliers

This comprehensive five-country report contains 820 pages, 320 tables, and presents analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The

USD 14500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available